ZEB1 and breast cancer: Proof-of-principle validation of this idea was shown experimentally, where breaking the feedback loop between Zeb and miR-200 by CRISPR/Cas9-based edition of Zeb1 binding sites in the promoter region of miR-200s reduced the metastatic potential of breast cancer in vivo (53).